Arcturus Therapeutics Holdings Inc
ARCT12.200USD
-0.100-0.81%
Cierre 08/04, 16:00（ET）Cotizaciones retrasadas 15 min
330.88MCap. mercado
PérdidaP/E TTM
Más Datos de Arcturus Therapeutics Holdings Inc Compañía
Arcturus Therapeutics Holdings Inc. is a global messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. It is leveraging its LUNAR platform and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.
Información de la empresa
Símbolo de cotizaciónARCT
Nombre de la empresaArcturus Therapeutics Holdings Inc
Fecha de salida a bolsaMay 22, 2013
Director ejecutivoMr. Joseph E. Payne
Número de empleados174
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 22
Dirección10628 Science Center Dr Ste 250
CiudadSAN DIEGO
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal92121-1132
Teléfono18589002660
Sitio Webhttps://arcturusrx.com/
Símbolo de cotizaciónARCT
Fecha de salida a bolsaMay 22, 2013
Director ejecutivoMr. Joseph E. Payne
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Joseph E. Payne
Mr. Joseph E. Payne
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.48M
--
Dr. Padmanabh Chivukula
Dr. Padmanabh Chivukula
Chief Operating Officer, Chief Scientific Officer
Chief Operating Officer, Chief Scientific Officer
435.33K
--
Mr. Lance Kurata
Mr. Lance Kurata
Chief Legal Officer
Chief Legal Officer
--
--
Dr. Adm. Jing L. Marantz, M.D., Ph.D.
Dr. Adm. Jing L. Marantz, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Edward W. Holmes, M.D.
Dr. Edward W. Holmes, M.D.
Independent Director
Independent Director
--
--
Mr. James F. Barlow
Mr. James F. Barlow
Independent Director
Independent Director
--
--
Dr. John H. Markels, Ph.D.
Dr. John H. Markels, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Andrew H. (Andy) Sassine
Mr. Andrew H. (Andy) Sassine
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Joseph E. Payne
Mr. Joseph E. Payne
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.48M
--
Dr. Padmanabh Chivukula
Dr. Padmanabh Chivukula
Chief Operating Officer, Chief Scientific Officer
Chief Operating Officer, Chief Scientific Officer
435.33K
--
Mr. Lance Kurata
Mr. Lance Kurata
Chief Legal Officer
Chief Legal Officer
--
--
Dr. Adm. Jing L. Marantz, M.D., Ph.D.
Dr. Adm. Jing L. Marantz, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Edward W. Holmes, M.D.
Dr. Edward W. Holmes, M.D.
Independent Director
Independent Director
--
--
Mr. James F. Barlow
Mr. James F. Barlow
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Federated Hermes Global Investment Management Corp.
17.31%
BlackRock Institutional Trust Company, N.A.
7.82%
Nikko Asset Management Co., Ltd.
6.76%
The Vanguard Group, Inc.
6.67%
ARK Investment Management LLC
6.32%
Other
55.12%
Accionistas
Accionistas
Proporción
Federated Hermes Global Investment Management Corp.
17.31%
BlackRock Institutional Trust Company, N.A.
7.82%
Nikko Asset Management Co., Ltd.
6.76%
The Vanguard Group, Inc.
6.67%
ARK Investment Management LLC
6.32%
Other
55.12%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
43.62%
Investment Advisor
28.78%
Hedge Fund
13.66%
Individual Investor
7.88%
Research Firm
5.21%
Insurance Company
1.01%
Pension Fund
0.52%
Bank and Trust
0.30%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
391
27.00M
99.57%
-3.36M
2025Q1
403
27.75M
102.37%
-3.11M
2024Q4
400
27.43M
101.26%
-2.26M
2024Q3
404
26.95M
99.66%
-3.33M
2024Q2
409
27.79M
102.77%
-2.68M
2024Q1
391
28.99M
107.82%
+144.88K
2023Q4
376
27.09M
101.05%
-1.26M
2023Q3
373
26.77M
100.23%
-170.02K
2023Q2
355
26.49M
99.74%
-2.09M
2023Q1
361
26.10M
98.32%
-2.45M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Federated Hermes Global Investment Management Corp.
4.69M
17.31%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.12M
7.82%
-29.89K
-1.39%
Mar 31, 2025
Nikko Asset Management Co., Ltd.
1.93M
7.1%
-138.97K
-6.73%
Mar 31, 2025
The Vanguard Group, Inc.
1.74M
6.43%
+64.37K
+3.83%
Mar 31, 2025
ARK Investment Management LLC
2.01M
7.41%
+74.63K
+3.86%
Mar 31, 2025
Payne (Joseph E)
1.48M
5.46%
--
--
Apr 08, 2025
State Street Global Advisors (US)
1.28M
4.72%
-45.71K
-3.45%
Mar 31, 2025
Balyasny Asset Management LP
938.19K
3.46%
+389.43K
+70.97%
Mar 31, 2025
Schonfeld Strategic Advisors LLC
825.77K
3.04%
-23.32K
-2.75%
Mar 31, 2025
Woodline Partners LP
780.44K
2.88%
-26.47K
-3.28%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
ARK Genomic Revolution ETF
2.14%
WisdomTree BioRevolution Fund
1.67%
Virtus LifeSci Biotech Clinical Trials ETF
0.93%
iShares Genomics Immunology and Healthcare ETF
0.74%
AXS Green Alpha ETF
0.54%
Global X Genomics & Biotechnology ETF
0.41%
ALPS Medical Breakthroughs ETF
0.24%
SPDR S&P Biotech ETF
0.12%
iShares Micro-Cap ETF
0.07%
Direxion Daily S&P Biotech Bull 3X Shares
0.07%
Ver más
ARK Genomic Revolution ETF
Proporción2.14%
WisdomTree BioRevolution Fund
Proporción1.67%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.93%
iShares Genomics Immunology and Healthcare ETF
Proporción0.74%
AXS Green Alpha ETF
Proporción0.54%
Global X Genomics & Biotechnology ETF
Proporción0.41%
ALPS Medical Breakthroughs ETF
Proporción0.24%
SPDR S&P Biotech ETF
Proporción0.12%
iShares Micro-Cap ETF
Proporción0.07%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.07%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
